PYK2 promotes HER2-positive breast cancer invasion

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-9966
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
PYK2 promotes HER2-positive breast cancer invasion ; volume:38 ; number:1 ; day:22 ; month:5 ; year:2019 ; pages:1-14 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (22.5.2019), 1-14, 12.2019

Creator
Al-Juboori, Shaymaa IK
Vadakekolathu, Jayakumar
Idri, Sarra
Wagner, Sarah
Zafeiris, Dimitrios
Pearson, Joshua RD
Almshayakhchi, Rukaia
Caraglia, Michele
Desiderio, Vincenzo
Miles, Amanda K.
Boocock, David J.
Ball, Graham R.
Regad, Tarik
Contributor
SpringerLink (Online service)

DOI
10.1186/s13046-019-1221-0
URN
urn:nbn:de:101:1-2019111613021234533863
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Al-Juboori, Shaymaa IK
  • Vadakekolathu, Jayakumar
  • Idri, Sarra
  • Wagner, Sarah
  • Zafeiris, Dimitrios
  • Pearson, Joshua RD
  • Almshayakhchi, Rukaia
  • Caraglia, Michele
  • Desiderio, Vincenzo
  • Miles, Amanda K.
  • Boocock, David J.
  • Ball, Graham R.
  • Regad, Tarik
  • SpringerLink (Online service)

Other Objects (12)

SIRT6 promotes metastasis and relapse in HER2-positive breast cancer

SIRT6 promotes metastasis and relapse in HER2-positive breast cancer

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers

How We Treat HER2-Positive Metastatic Breast Cancer

How We Treat HER2-Positive Metastatic Breast Cancer

Nanotechnology approaches to addressing HER2-positive breast cancer

Nanotechnology approaches to addressing HER2-positive breast cancer

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

ASCO 2019: highlights in HER2-positive metastatic breast cancer

ASCO 2019: highlights in HER2-positive metastatic breast cancer

ASCO 2018: highlights in HER2-positive metastatic breast cancer

ASCO 2018: highlights in HER2-positive metastatic breast cancer

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016

Related objects